United Therapeutics Q3 revenue misses estimates

United Therapeutics

29/10/2025 10:37

Overview

United Therapeutics Q3 revenue grows 7% yr/yr but misses analyst expectations

Net income for Q3 rises 10% yr/yr to $338.7 mln

Company repurchased $1 bln of common stock in Q3

Outlook

United Therapeutics did not provide specific financial guidance for future periods

Result Drivers

TYVASO DPI GROWTH - Increased quantities sold and price rise drove 22% revenue growth for Tyvaso DPI

ORENITRAM SALES - Orenitram revenues increased 16% due to higher quantities sold and price increase

TETON-2 STUDY IMPACT - Breakthrough TETON-2 study results in idiopathic pulmonary fibrosis could broaden therapeutic reach

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$799.50 mln
$817 mln (10 Analysts)
Q3 EPS
$7.16
Q3 Net Income
$338.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for United Therapeutics Corp is $500.00, about 16.9% above its October 28 closing price of $415.34

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release: ID:nBw66csQca

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)